Want to see HK:6622 full AI Analyst Report?
6622 Stock Chart & Stats
HK$3.17
HK$0.01(0.78%)
At close: 4:00 PM EST
HK$3.17
HK$0.01(0.78%)
Day’s Range― - ―
52-Week RangeHK$2.38 - HK$3.85
Previous CloseN/A
Volume310.50K
Average Volume (3M)161.85K
Market Cap
HK$1.40B
Enterprise ValueHK$515.77
Total Cash (Recent Filing)HK$1.01B
Total Debt (Recent Filing)HK$266.51M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,839,000
10 Day Avg. Volume136,860
30 Day Avg. Volume161,853
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetModest leverage and a sizable equity base provide some financial resilience while the company funds its ophthalmology pipeline. This cushion may reduce immediate balance-sheet pressure and preserve flexibility for development and commercialization, although continued losses could erode it over time.
Focused Ophthalmology PlatformA dedicated ophthalmology focus gives Zhaoke a coherent platform for building and advancing related therapies rather than operating across unrelated fields. Concentrated expertise and a portfolio approach can support repeat commercialization capabilities as additional products progress toward market.
Revenue Base And Improving Cash TrendThe company has established commercial revenue and showed some year-over-year improvement in free cash flow, even though cash generation remains negative. If sustained, a growing revenue base and reduced burn could gradually improve operating leverage and lower future financing pressure.
Bears Say
Unstable And Declining RevenueThe sharp revenue contraction demonstrates that commercial traction is not yet consistent and makes the current business model difficult to scale predictably. Unstable sales can constrain investment in the pipeline, weaken operating leverage, and make future funding requirements more difficult to plan.
Persistent Deep LossesPersistent operating and net losses, combined with negative gross profit in 2025, indicate that revenue currently does not cover the cost of generating sales. Until margins recover, growth may increase financial requirements rather than create self-funded earnings power or durable shareholder returns.
Sustained Cash BurnOngoing operating and free cash flow consumption means the business is not currently funding development and operations internally. If the pattern continues, reliance on capital raises or additional debt could dilute existing holders, increase financing risk, and limit strategic flexibility.
Zhaoke Ophthalmology Ltd. News
6622 FAQ
What was Zhaoke Ophthalmology Ltd.’s price range in the past 12 months?
Zhaoke Ophthalmology Ltd. lowest stock price was HK$2.38 and its highest was HK$3.85 in the past 12 months.
What is Zhaoke Ophthalmology Ltd.’s market cap?
Zhaoke Ophthalmology Ltd.’s market cap is HK$1.40B.
When is Zhaoke Ophthalmology Ltd.’s upcoming earnings report date?
Zhaoke Ophthalmology Ltd.’s upcoming earnings report date is Mar 29, 2027 which is in 183 days.
How were Zhaoke Ophthalmology Ltd.’s earnings last quarter?
Zhaoke Ophthalmology Ltd. released its earnings results on Aug 28, 2026. The company reported -HK$0.255 earnings per share for the quarter.
Is Zhaoke Ophthalmology Ltd. overvalued?
According to Wall Street analysts Zhaoke Ophthalmology Ltd.’s price is currently Overvalued.
Does Zhaoke Ophthalmology Ltd. pay dividends?
Zhaoke Ophthalmology Ltd. does not currently pay dividends.
What is Zhaoke Ophthalmology Ltd.’s EPS estimate?
Zhaoke Ophthalmology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhaoke Ophthalmology Ltd. have?
Zhaoke Ophthalmology Ltd. has 548,839,000 shares outstanding.
What happened to Zhaoke Ophthalmology Ltd.’s price movement after its last earnings report?
Zhaoke Ophthalmology Ltd. reported an EPS of -HK$0.255 in its last earnings report. Following the earnings report the stock price went down -0.769%.
Which hedge fund is a major shareholder of Zhaoke Ophthalmology Ltd.?
Currently, no hedge funds are holding shares in HK:6622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhaoke Ophthalmology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.